A novel circRNA marker for gastric cancer diagnosis, treatment and prognosis and its application
By discovering the mitochondrial gene-encoded circRNA Mito-circRNR2, the lack of early diagnosis and treatment targets for gastric cancer is solved, and the reprogramming and migration inhibition of gastric cancer cells is achieved, providing new diagnostic and therapeutic methods.
Patent Information
- Application Number
- CN202211565876.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-07
- Publication Date
- 2025-03-25
- Estimated Expiration
- 2042-12-07
AI Technical Summary
There is a lack of early diagnostic markers and effective therapeutic targets for gastric cancer, which leads to the development of the disease to the middle and late stages and has poor efficacy.
A novel circRNA, Mito-circRNR2, encoded by mitochondrial genes, was discovered and used as a diagnostic marker and therapeutic target for gastric cancer. This circRNA mediates the reprogramming of gastric cancer cells by inhibiting oxidative phosphorylation and promoting glycolysis, and promotes the migration of gastric cancer cells.
Mito-circRNR2 is highly expressed in gastric cancer tissues and can serve as an early diagnostic biomarker for gastric cancer. By inhibiting its expression, it inhibits gastric cancer cell migration, providing a potential therapeutic target.